How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market
- By Therapeutic Class: Androgen Receptor Inhibitors, Chemotherapy Agents, Immunotherapy, Radiopharmaceuticals, PARP Inhibitors
- By Treatment Modality: Monotherapy, Combination Therapy
- By Disease Stage: Non-Metastatic CRPC (nmCRPC), Metastatic CRPC (mCRPC), Hormone-Sensitive Prostate Cancer (HSPC)
- By Mechanism of Action: Androgen Deprivation Therapy (ADT), Androgen Receptor Signaling Inhibitors (ARSI), DNA Damage Repair (DDR) Inhibitors, Immune Checkpoint Inhibitors
- By Patient Population: Chemotherapy-Naïve Patients, Post-Chemotherapy Patients, Patients with Bone Metastases
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Androgen Receptor Inhibitors leads By Therapeutic Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Class 5
Treatment Modality 2
Disease Stage 3
Mechanism of Action 4
Patient Population 3
Companies profiled
Johnson & Johnson (Janssen Pharmaceuticals)
Astellas Pharma Inc.
Pfizer Inc.
Bayer AG
Novartis AG
Sanofi S.A.
Amgen Inc.
Bristol-Myers Squibb
Daiichi Sankyo Company
Limited
Exelixis Inc.
Ipsen S.A.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson (Janssen Pharmaceuticals)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Astellas Pharma Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Amgen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Daiichi Sankyo Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Exelixis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ipsen S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Eli Lilly and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Merck & Co. Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →AbbVie Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Takeda Pharmaceutical Company Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,223M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Androgen Receptor Inhibitors50.7
- Chemotherapy Agents10.9
- Immunotherapy13.1
- Radiopharmaceuticals9.6
- PARP Inhibitors15.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$781.4M → $1,827M · 11.2%
Europe$544.6M → $1,087M · 9.0%
Asia Pacific$497.2M → $1,183M · 11.4%
Latin America$307.8M → $710.3M · 11.0%
Middle East and Africa$236.8M → $513.7M · 10.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.342026
10.362027
10.372028
10.392029
10.402030
10.412031
10.422032
10.432033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson (Janssen Pharmaceuticals)16.1
- Astellas Pharma Inc.21.7
- Pfizer Inc.7.1
- Bayer AG11.0
- Novartis AG8.1
- Sanofi S.A.8.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Class21.3%
Treatment Modality12.6%
Disease Stage25.2%
Mechanism of Action18.0%
Patient Population22.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.3
- Europe20.4
- Asia Pacific22.2
- Latin America13.3
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson (Janssen Pharmaceuticals) | 79 | 88 | 76 | 85 | 85 | 94 | 85 |
| Astellas Pharma Inc. | 81 | 86 | 73 | 80 | 74 | 70 | 77 |
| Pfizer Inc. | 71 | 69 | 79 | 64 | 72 | 82 | 73 |
| Bayer AG | 61 | 78 | 81 | 60 | 75 | 65 | 70 |
| Novartis AG | 62 | 62 | 63 | 65 | 71 | 64 | 65 |
| Sanofi S.A. | 46 | 60 | 66 | 48 | 52 | 60 | 55 |
| Amgen Inc. | 48 | 48 | 50 | 58 | 42 | 44 | 48 |
| Bristol-Myers Squibb | 39 | 59 | 41 | 53 | 40 | 38 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson (Janssen Pharmaceuticals)
- Astellas Pharma Inc.
- Pfizer Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson (Janssen Pharmaceuticals) | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Astellas Pharma Inc. | ◐ | ◐ | − | ✓ | ◐ | ◐ |
| Pfizer Inc. | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| Bayer AG | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Novartis AG | ◐ | − | − | ◐ | ◐ | ◐ |
| Sanofi S.A. | − | ◐ | − | − | − | ◐ |
| Amgen Inc. | − | − | ◐ | − | − | − |
| Bristol-Myers Squibb | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Johnson & Johnson (Janssen Pharmaceuticals)85
2Astellas Pharma Inc.77
3Pfizer Inc.73
4Bayer AG70
5Novartis AG65
6Sanofi S.A.55
7Amgen Inc.48
8Bristol-Myers Squibb45
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Johnson & Johnson (Janssen Pharmaceuticals)
Challenger3
Strong scale, closing on the leaders.
Astellas Pharma Inc.Pfizer Inc.Bayer AG
Contender1
Focused players with pockets of strength.
Novartis AG
Niche3
Specialists in a single segment or region.
Sanofi S.A.Amgen Inc.Bristol-Myers Squibb
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Class in North America, then scale across Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market — a $487M beachhead inside a $7.66B market.
Beachhead (SOM)$487Mobtainable near-term
Serviceable (SAM)$2.62Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Androgen Receptor Inhibitors
Best fit — highest urgency & budget in Therapeutic Class.
Economic buyer75 fit
Chemotherapy Agents
Strong fit — clear ROI and a fast path to value.
End user68 fit
Immunotherapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Disease Stage
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel31%
Digital / self-serve17%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation12%
Closed-won6%
$12.3KCAC
$58KLTV
4.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market is a resilient opportunity — $4.29B by 2033, compounding at 5.7%.
TAM · 2025$2.75Btoday
TAM · 2033$4.29Bforecast
CAGR5.7%2027–2033
Cumulative$31.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.29BTotal addressable market
SAM$1.61BServiceable available market
SOM$325MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.7% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Class moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.29BLarge & growingTAM by 2033 at 5.7% CAGR
$1.61BServiceable nowreachable with today’s model
$325MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.35BBear3.7% CAGR
$4.29BBase5.7% CAGR
$5.49BBull7.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market — a $9.26B market by 2033. Plan: grow share from 5.8% to 11.6%.
Market size · 2033$9.26Btotal addressable
Market CAGR10.2%2027–2033
Target share11.6%from 5.8% today
Revenue ambition$1.07Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.8% | 11.6% | Behind |
| Revenue | $521M | $1.07B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.0% | 43.9% | On track |
| Customer retention | 90.5% | 96.2% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $115M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market conversation — a $8.47B market you can size, segment and defend in minutes.
Market size · 2033$8.47Btotal opportunity
Growth9.8%CAGR to 2033
Addressable buyers1,265+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Class
Goal Grow share in Therapeutic Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 4 mopayback period
$42K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Johnson & Johnson (Janssen Pharmaceuticals)Astellas Pharma Inc.Pfizer Inc.Bayer AGNovartis AGSanofi S.A.Amgen Inc.Bristol-Myers Squibb+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Castration-Resistant Prostate Cancer (CRPC) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportCastration-Resistant Prostate Cancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCast-Resin Bus Duct Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCasual Dining Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCasual Dining Restaurant Chains Market
Market size, share, segmentation and regional forecast.
$926M market · 2025 base year
View reportCasual Sandal Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportCasual Sneaker Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCasualty Treaty Reinsurance Market
Market size, share, segmentation and regional forecast.
$398M market · 2025 base year
View reportCat And Dog Hair Dryer Market
Market size, share, segmentation and regional forecast.
$680M market · 2025 base year
View reportCat bed Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportCat Cage Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportCat Chewing Sticks Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.